# Darbepoetin alfa

## NESP inj 20mcg(洗腎用)

| TAH Drug Code      | [INESP](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=INESP){:target="_blank"}                                                                                                                                                                                                                                                      |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Anemia: Treatment of anemia due to concurrent myelosuppressive chemotherapy in patients with cancer (nonmyeloid malignancies) receiving chemotherapy (palliative intent) for a planned minimum of 2 additional months of chemotherapy; treatment of anemia due to chronic kidney disease (including patients on dialysis and not on dialysis) |
| Dosing             | Initial dose as 0.45mcg/kg IV or SC every week for treatment of chronic renal failure patient with anemia, keeping Hb between 10-12g/dL. For patient with chemotherapy, 2.25mcg/kg SC as initial dose.                                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to darbepoetin or any component of the formulation; uncontrolled hypertension; pure red cell aplasia (due to darbepoetin or other erythropoietin protein drugs)                                                                                                                                                              |
| Adverse Effects    | Hypertension (31%), peripheral edema (17%), edema (6% to 13%), Abdominal pain (10% to 13%), Dyspnea (17%), cough (12%)                                                                                                                                                                                                                        |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/darbepoetin-alfa-drug-information){:target="_blank"}                                                                                                                                                                                                                                             |

